By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
DrugPatentWatch Database Preview
Anti-coagulant Drug Class List
Email this page to a colleague
Drugs in Drug Class: Anti-coagulant
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz Inc | ANGIOMAX | bivalirudin | INJECTABLE;INTRAVENOUS | 020873-001 | Dec 15, 2000 | AP | RX | Yes | Yes | Get Started Free | Get Started Free | Y | Get Started Free | ||
| Sandoz Inc | ANGIOMAX | bivalirudin | INJECTABLE;INTRAVENOUS | 020873-001 | Dec 15, 2000 | AP | RX | Yes | Yes | Get Started Free | Get Started Free | Y | Get Started Free | ||
| Maia Pharms Inc | ANGIOMAX RTU | bivalirudin | SOLUTION;INTRAVENOUS | 211215-001 | Jul 25, 2019 | RX | Yes | Yes | Get Started Free | Get Started Free | Get Started Free | ||||
| Amneal Pharms Co | ARGATROBAN | argatroban | INJECTABLE;INJECTION | 206698-001 | Jan 26, 2018 | AP | RX | No | No | Get Started Free | Get Started Free | Get Started Free | |||
| Caplin | ARGATROBAN | argatroban | INJECTABLE;INJECTION | 214235-001 | Jan 21, 2021 | AP | RX | No | No | Get Started Free | Get Started Free | Get Started Free | |||
| Novartis | ARGATROBAN | argatroban | INJECTABLE;INJECTION | 020883-001 | Jun 30, 2000 | AP | RX | Yes | Yes | Get Started Free | Get Started Free | Get Started Free | |||
| Mylan Institutional | ARGATROBAN | argatroban | INJECTABLE;INJECTION | 202626-001 | Jun 30, 2014 | AP | RX | No | No | Get Started Free | Get Started Free | Get Started Free | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
